Complicaciones de la enfermedad de Parkinson relacionadas con la infección por SARS-CoV-2
Complications of Parkinson’s Disease related to SARS-CoV-2 infectionContenido principal del artículo
El SARS-CoV-2 fue registrada en la ciudad de Wuhan-China, por primera vez en diciembre de 2019. El impacto de esta nueva patología en pacientes con Enfermedad de Parkinson fue negativo, por cuanto puso al descubierto el desarrollo de complicaciones graves posteriores a esta infección, Además, el virus puede afectar indirectamente el sistema nervioso central a través de la respuesta inflamatoria y la liberación de citocinas, lo que puede tener un impacto negativo en la función neuronal, conduciendo a una mayor afectación en la calidad de vida de estos pacientes. Objetivo. Describir las complicaciones de la Enfermedad de Parkinson relacionadas con la infección por SARS-CoV-2. Metodología. Se realizó una revisión sistemática, a través de una búsqueda en bases de datos. En donde se incluyeron estudios publicados entre 2019 y 2022, que cumplan criterios de inclusión y exclusión, e informen sobre las complicaciones en pacientes con enfermedad de Parkinson. Resultados. Se procedió a la lectura de texto completo de cada artículo, siendo excluidos 13 artículos, debido a que no cumplían totalmente con criterios de inclusión, presentaban otra temática o tenían una metodología poco clara, resultados 17 como resultado. Conclusión. Es importante reconocer que el COVID-19 es una enfermedad multifacética que afecta principalmente al sistema respiratorio, pero también puede tener impactos en otros sistemas del cuerpo, incluido el sistema nervioso. Si bien se ha observado que algunos pacientes con Parkinson experimentan un empeoramiento de los síntomas motores y no motores durante la infección por COVID-19, entre los síntomas que más mayor prevalencia de complicaciones presentaron se encuentran las alteraciones del sueño, alteraciones del estado de ánimo, bradicinesia, rigidez, temblor, alteraciones de la marcha.
SARS-CoV-2 was recorded in Wuhan City-China for the first time in December 2019. The impact of this new pathology in patients with Parkinson's Disease was negative, in that it uncovered the development of severe complications following this infection, in addition, the virus may indirectly affect the central nervous system through inflammatory response and cytokine release, which may have a negative impact on neuronal function, leading to further impairment in the quality of life of these patients. Objective. To describe the complications of Parkinson's disease related to SARS-CoV-2 infection. Methodology. A systematic review was carried out through a database search. We included studies published between 2019 and 2022 that met inclusion and exclusion criteria and reported on complications in patients with Parkinson's disease. Results. We proceeded to read the full text of each article, being excluded 13 articles, because they did not fully meet inclusion criteria, presented another subject or had an unclear methodology, 17 as a result. Conclusion. It is important to recognize that COVID-19 is a multifaceted disease that primarily affects the respiratory system, but can also have impacts on other body systems, including the nervous system. While it has been observed that some Parkinson's patients experience worsening of motor and non-motor symptoms during COVID-19 infection, among the symptoms with the highest prevalence of complications were sleep disturbances, mood disturbances, bradykinesia, rigidity, tremor, gait disturbances.
Descargas
Detalles del artículo
Yüce M, Filiztekin E, Özkaya KG. COVID-19 diagnosis -A review of current methods. Biosens Bioelectron. 2021; 172:112752. doi: 10.1016/j.bios.2020.112752
Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 2021;20(5):385-397. doi: 10.1016/S1474-4422(21)00030
Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021, 12;397(10291):2284-2303. DOI: 10.1016/S0140-6736(21)00218-X
Merello M, Bhatia KP, Obeso JA. SARS-CoV-2 and the risk of Parkinson's disease: facts and fantasy. Lancet Neurol. 2021 Feb;20(2):94-95. doi: 10.1016/S1474-4422(20)30442-7
Ochani R, Asad A, Yasmin F, Shaikh S, Khalid H, Batra S, Sohail MR, Mahmood SF, Ochani R, Hussham Arshad M, Kumar A, Surani S. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infez Med. 2021;29(1):20-36. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33664170/
Zhang Y, Xu X. Chinese Herbal Medicine in the Treatment of Depression in Parkinson's Disease: From Molecules to Systems. Front Pharmacol. 2022;13:879459. doi: 10.3389/fphar.2022.879459
Shalash AS, Hassan DM, Elrassas HH, Salama MM, Me?ndez-Herna?ndez E, Salas- Pacheco JM, Arias-Carrio?n O. Los potenciales evocados auditivos y vestibulares se correlacionan con caracteri?sticas motoras y no motoras de la enfermedad de Parkinson. Neurol frontal. 2017; 8:55. DOI: 10.3389/fneur.2017.00055
Antonini A, Leta V, Teo J, Chaudhuri KR. Outcome of Parkinson's Disease Patients Affected by COVID-19. Mov Disord. 2020;35(6):905-908. doi: 10.1002/mds.28104
Hainque E, Grabli D. Rapid worsening in Parkinson's disease may hide COVID-19 infection. Parkinsonism Relat Disord. 2020; 75:126-127. doi: 10.1016/j.parkreldis.2020.05.008
Ahmad Malik J, Ahmed S, Shinde M, Almermesh MHS, Alghamdi S, Hussain A, Anwar S. The Impact of COVID-19 On Comorbidities: A Review of Recent Updates for Combating It. Saudi J Biol Sci. 2022;29(5):3586-3599. doi: 10.1016/j.sjbs.2022.02.006
Shalash A, Roushdy T, Essam M, Fathy M, Dawood NL, Abushady EM, Elrassas H, Helmi A, Hamid E. Mental Health, Physical Activity, and Quality of Life in Parkinson's Disease During COVID-19 Pandemic. Mov Disord. 2020;35(7):1097-1099. doi: 10.1002/mds.28134
Prasad S, Holla VV, Neeraja K, Surisetti BK, Kamble N, Yadav R, Pal PK. Parkinson's Disease and COVID-19: Perceptions and Implications in Patients and Caregivers. Mov Disord. 2020;35(6):912-914. doi: 10.1002/mds.28088
Lo Monaco MR, Bentivoglio AR, Fusco D, Calabresi P, Piano C. Subacute onset dystonia in a woman affected by Parkinson’s disease following SARS-COV-2 infection. Clin Park Relat Disord. 2021;100082. DOI: 10.1016/j.prdoa.2020.100082
Salari M, Zali A, Ashrafi F, Etemadifar M, Sharma S, Hajizadeh N, Ashourizadeh H. Incidence of Anxiety in Parkinson's Disease During the Coronavirus Disease (COVID-19) Pandemic. Mov Disord. 2020;35(7):1095-1096. doi: 10.1002/mds.28116
Brown EG, Chahine LM, Goldman SM, Korell M, Mann E, Kinel DR, Arnedo V, Marek KL, Tanner CM. The Effect of the COVID-19 Pandemic on People with Parkinson's Disease. J Parkinsons Dis. 2020;10(4):1365-1377. doi: 10.3233/JPD-202249
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683-690. doi: 10.1001/jamaneurol.2020.1127
Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, Dequanter D, Blecic S, El Afia F, Distinguin L, Chekkoury-Idrissi Y, Hans S, Delgado IL, Calvo-Henriquez C, Lavigne P, Falanga C, Barillari MR, Cammaroto G, Khalife M, Leich P, Souchay C, Rossi C, Journe F, Hsieh J, Edjlali M, Carlier R, Ris L, Lovato A, De Filippis C, Coppee F, Fakhry N, Ayad T, Saussez S. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(8):2251-2261. DOI: 10.1007/s00405-020-05965-1
Schirinzi T, Cerroni R, Di Lazzaro G, Liguori C, Scalise S, Bovenzi R, Conti M, Garasto E, Mercuri NB, Pierantozzi M, Pisani A, Stefani A. Self-reported needs of patients with Parkinson's disease during COVID-19 emergency in Italy. Neurol Sci. 2020;41(6):1373-1375. doi: 10.1007/s10072-020-04442-1
Santos-García D, Oreiro M, Pérez P, Fanjul G, Paz González JM, Feal Painceiras MJ, Cores Bartolomé C, Valdés Aymerich L, García Sancho C, Castellanos Rodrigo MDM. Impact of Coronavirus Disease 2019 Pandemic on Parkinson's Disease: A Cross-Sectional Survey of 568 Spanish Patients. Mov Disord. 2020;35(10):1712-1716. doi: 10.1002/mds.28261
El-Qushayri AE, Ghozy S, Reda A, Kamel AMA, Abbas AS, Dmytriw AA. The impact of Parkinson's disease on manifestations and outcomes of Covid-19 patients: A systematic review and meta-analysis. Rev Med Virol. 2022;32(2): e2278. doi: 10.1002/rmv.2278
Del Prete E, Francesconi A, Palermo G, Mazzucchi S, Frosini D, Morganti R, Coleschi P, Raglione LM, Vanni P, Ramat S, Novelli A, Napolitano A, Battisti C, Giuntini M, Rossi C, Menichetti C, Ulivelli M, De Franco V, Rossi S, Bonuccelli U, Ceravolo R; Tuscany Parkinson COVID-19 Participants. Prevalence and impact of COVID-19 in Parkinson's disease: evidence from a multi-center survey in Tuscany region. J Neurol. 2021;268(4):1179-1187. doi: 10.1007/s00415-020-10002-6
Artusi CA, Romagnolo A, Imbalzano G, Marchet A, Zibetti M, Rizzone MG, Lopiano L. COVID-19 in Parkinson's disease: Report on prevalence and outcome. Parkinsonism Relat Disord. 2020; 80:7-9. doi: 10.1016/j.parkreldis.2020.09.008
Khoshnood RJ, Zali A, Tafreshinejad A, Ghajarzadeh M, Ebrahimi N, Safari S, Mirmosayyeb O. Parkinson's disease and COVID-19: a systematic review and meta-analysis. Neurol Sci. 2022;43(2):775-783. DOI: 10.1007/s10072-021-05756-4
Fasano A, Elia AE, Dallocchio C, Canesi M, Alimonti D, Sorbera C, Alonso-Canovas A, Pezzoli G. Predictors of COVID-19 outcome in Parkinson's disease. Parkinsonism Relat Disord. 2020; 78:134-137. doi: 10.1016/j.parkreldis.2020.08.012